ArticleFrontiers in immunology2026
Vaping induces a marked pro-inflammatory state within the lung, which is at least partially due to its immunomodulatory effects.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Introduction: E-cigarette use or "vaping" exposes the lungs to a large array of chemicals, flavors and nicotine. Initially marketed as a healthier alternative to tobacco use, research has since begun to demonstrate vaping plays a role in immune dysfunction and inflammation, with both similarities and differences in effects observed compared with tobacco use. One potential mechanism of immune dysfunction is related to the regulation of monocyte-derived suppressor cells (MDSCs). MDSCs are a heterogenous population of cells that are generated and expand during inflammation and infection and are known and are commonly described as having immunosuppressive roles. MDSCs play an important role in modulating and suppressing immune response. However, vaping exposure may, in part, be associated with modifications in MDSC populations and inflammatory processes. Thus, we questioned whether vaping modulates MDSCs, potentially resulting in alterations in inflammatory cells and mediators in vivo. Methods: Briefly, male and female mice were vaped with JUUL Menthol (3% nicotine) pods using the SCIREQ InExpose system for 4 weeks. After 4 weeks, the mice were then exposed to lipopolysaccharide (LPS) to mimic a bacterial infection. Post-infection (24 hours) the mice were sacrificed, and bronchoalveolar lavage fluid (BALF) was collected. Results: Vaped mice that were challenged with LPS demonstrated a decrease in macrophage numbers and significantly lower levels of granulocytic/ polymorphonuclear myeloid-derived (PMN) -MDSC compared to mice treated with LPS alone or only vaped. In contrast, monocytic (M) -MDSC numbers increased in the vaped and LPS challenged mice compared to the mice only treated with LPS in females while in males exhibited a decrease in vape+LPS groups compared to LPS alone. When comparing these results to the inflammatory data, several cytokines and chemokines linked to M-MDSC development and function were expressed after only LPS treatment but not by the dual vape+LPS treatment. However, exceptions were IFN-γ and RANTES/CCL5, which were increased after the dual treatment. Discussion: These data suggest that the variation in cytokine and chemokine levels is associated with changes in M-MDSC populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.